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Abnormalities of the p53 tumour suppressor gene are among the
most prevalent molecular events, and they contribute to tumori-
genesis in over 50% of all human cancers (Hollstein et al, 1991;
Levine et al, 1991; Greenblatt et al, 1994). However, despite the
widespread presence of p53 mutations in human cancers, many
tumours develop in the absence of p53 abnormalities or obvious
tumour-specific antigens (Weinberg, 1993), most likely due to the
involvement of other mechanisms of inactivating p53 or the loss of
other tumour suppressor genes. 
The first p53-related proteins, p73a and b, have been reported
by Kaghad et al to be potentially invovled in the development of
neuroblastoma (Kaghad et al, 1997). Jost et al have reported that
p73 can induce apoptosis in tumour cells when overexpressed in a
p53-independent manner (Jost et al, 1997). Laurenzi et al and
Ueda et al have recently identified other p73 splice variants, p73g,
d and e, and suggested that these five p73 isoforms may differen-
tially modulate the functions of p53 and p73 molecules (Laurenzi
et al, 1998; Ueda et al, 1999). It is important to note that some of
the regulatory mechanisms of p53 are implicated in the regulation
of p73 functions by distinct mechanisms as revealed by tumour-
derived mutant p53 (Di Como et al, 1999), mdm2 oncoprotein
(Dobbelstein et al, 1999; Zeng et al, 1999) or viral oncoproteins
(Marin et al, 1998; Prabhu et al, 1998; Steegenga et al, 1999).
While proof of the biological importance of p73 has yet to be
provided, it is noteworthy that p53 is not an orphan gene but has a
family with structural and functional resemblance like other
tumour suppressors such as the retinoblastoma gene family (RB-1,
p107 and p130) and the p16INK4A-like cyclin-dependent kinase
(cdk) inhibitors (p15INK4B, p16INK4A, p18INK4C and p19INK4D). 
Recently, we and other groups have identified the second p53-
related gene, p73L/p63/p51/p40/KET, and cytogenetically mapped
it in chromosome region 3q27–8 (Schmale and Banberger, 1997;
Augustin et al, 1998; Osada et al, 1998; Senoo et al, 1998; Trink et
al, 1998; Yang et al, 1998; Kaelin, 1999; Prives and Hall, 1999).
The p73L/p63/p51/p40/KET gene mainly encodes 2 splice vari-
ants, p73L/DNp63 and p51/TAp63 by different exon usage at its
amino terminal regions (see Figure 1). Of the 2, p51 has a transac-
tivation domain at its amino terminus with low identities to those
of p73 (30%) and p53 (22%), while p73L completely lacks such a
transactivation domain (Augustin et al, 1998; Senoo et al, 1998;
Trink et al, 1998; Yang et al, 1998). The putative DNA-binding
domain (DBD) of p73L and p51 have high identities to those of
p73 (88%) and to p53 (61%). The putative oligomerization domain
of p73L and p51 also have high identities to those of p73 (65%)
and p53 (37%). Functionally, p51 has been reported to induce
growth suppression, apoptosis and up-regulate p21waf1/cip1 through
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human tumour cell lines and found that a novel isoform, termed DNp73L, was predominantly expressed in squamous cell carcinomas. The
expression profile of DNp73L/p73L/p51 in primary human skin cancer specimens showed that the expression of p51 was frequently lost (62%)
but was detected in all normal skin samples. In p51-expressing skin cancers, DNp73L expression was associated at a high frequency (75%)
though it was not detected in normal skin tissues. Transient co-transfection data indicate the possibility that DNp73L can inhibit p53-, and
more preferentially, p51-mediated transactivation. These data suggest that the loss of expression of p51 and/or the expression of DNp73L
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binding to the p53 regulatory elements (Osada et al, 1998; Yang
et al, 1998). In contrast, p73L has been shown to act as a
dominant-negative agent to suppress the transactivation activity of
both p53 and p51 (Yang et al, 1998). Although p51 is suspected to
be a tumour suppressor candidate, it does not seem to be
frequently mutated as is the case with p53 in human cancers (Nishi
et al, 1999; Sunahara et al, 1999; Park et al, 2000). However, no
evidence concerning the linkage between the expression of these
isoforms and human cancers has been documented so far. In this
study, we examined various human tumour cell lines as well as
primary human cancer specimens to investigate the potential
involvement of the p73L/p63/p51/p40/KET gene in the patho-
genesis of human cancers. 
MATERIALS AND METHODS 
Tissue specimens and cell lines 
Tumour samples were obtained with informed consent from 13
patients diagnosed histologically as having skin cancers at Tokai
University Hospital and Kitasato University Hospital. All tissues
were quickly frozen in liquid nitrogen and stored at – 80˚C until
use. 6 normal skin tissues were similarly obtained under surgical
treatment. These tissues were processed for preparation of RNA
with ISOGEN reagent (Nippon Gene, Tokyo, Japan) according to
the manufacturer’s instructions. The cell lines used in this study
were collected from several institutions as follows. A431 (epider-
moid carcinoma), NCI H460 (lung carcinoma), Daudi, K562
(leukemia), DLD1, HCT116, HT29, LoVo, SW480, SW620,
WiDR (colon carcinoma), HeLa (cervical carcinoma), LNCap,
PC-3 (prostate carcinoma), MCF7, SKBR3 (breast carcinoma) and
Saos-2 (osteogenic sarcoma) were obtained from American Type
Culture Collection (Rockville, MD). A549, Lu99, SBC3 and
SBC5 (lung carcinoma) were obtained from Japanese Cancer
Research Resources Bank (Osaka, Japan). Jurkat (leukaemia),
ME180 (cervical carcinoma), TE8, TE9, TE10 and TE11
(oesophageal carcinoma) were obtained from the Cell Resource
Center for Biomedical Research, Institute of Development, Aging
and Cancer, Tohoku University (Sendai, Japan). MKN-1, MKN-74
(stomach carcinoma) and Cos-7 (African green monkey kidney
cell line) were obtained from RIKEN Cell Bank (Tsukuba Science
City, Japan). Cells were grown in DMEM or RPMI supplemented
with 10% fetal bovine serum. The p53 status of each cell line was
as follows; p53 wild-type (WT): A549, NCl H460, LoVo, LNCap,
HCT116, MCF7, Daudi, SBC3, Lu99, HeLa and ME180; p53
mutant (mt): Saos-2, PC-3, SBC5, WiDR, SKBR3, K562, Jurkat,
MKN-1, MKN-74, TE8, TE9, TE10, TE11, A431, SW480,
SW620, HT29 and DLD1. Note that the 2 cervical cell lines
ME180 and HeLa were grouped with p53WT although they
harbour human papilloma viruses (HPV) which inactivate the
wild-type p53. Assignment of these 2 cell lines to either group did
not make a significant difference in the following statistical
analysis. 
RT-PCR/Southern blot analysis 
First-strand cDNAs were synthesized from 2 mg of total RNA using
cDNA Cycle Kit with random primers (Invitrogen, Carlsbad, CA).
The synthesized cDNA was used immediately for PCR amplifica-
tion or stored at – 20˚C for further analyses. Nested PCR was
performed to detect the p73L/p63/p51/p40/KET gene transcripts
with Mastercycler Gradient (Eppendorf, Hamburg, Germany) with
the following primer sets; 5TA or 5dN / 3N1 (1st PCR), 5TA or
5dN / 3N2 (2nd PCR) for detection of p51 and p73L transcripts,
respectively, and 5D1 / 3D (1st PCR), 5D2 / 3D (2nd PCR) for
detection of the common DNA binding domain (see Figure 1 for
the location of the primers). The first amplification was carried out
in 25 ml reaction mixture containing 1 ml of RT product through 30
cycles of 94˚C for 40s, 60˚C for 45s, 72˚C for 40s. The second
amplification was carried out in 25 ml reaction mixture containing
1 ml of the first PCR product through 35 cycles of the same condi-
tion described above. As a control, b-actin cDNA was amplified
with 1 ml of RT product through 32 cycles of 94˚C for 40s, 60˚C for
45s, 72˚C for 40s. The oligonucleotide primers used in this study
and the expected length of the products are listed in Table 2. The
PCR products were run on a 1.2% agarose gel, transferred onto
nylon membranes (Pall, Port Washington, NY) and the Southern
blots were hybridized with g-32P labelled oligonucleotide probes:
73L-R2 (indicated as N in Figure 1), 3N2 (indicated as D in Figure
1) and with a-32P labelled human b-actin cDNA probe (Clontech,
Palo Alto, CA) for control b-actin. Bands were exposed to Kodak
X-OMAT AR films for 3–4 h. 
Sequence analysis 
Nested PCR was performed as described above and the bands
were excised from the gel and purified using a QIAquick
Gel Extraction Kit (Qiagen, Inc, Santa Clarita, CA). The purified
DNA fragments were directly sequenced with both strands by
an ABI Prism 373 DNA sequencer (Perkin-Elmer, Foster City,
CA) using a Cycle sequencing kit (Perkin-Elmer) according
to the manufacturer’s protocol. To confirm the presence of
mutation, PCR products were blunt-ended and subcloned into the
EcoRV site in pBluescript II SK(+) vector (Stratagene, La Jolla,
CA) and multiple individual clones were subsequently
sequenced on both strands. For genomic sequencing, the intronic
primer pairs were used as described previously (Hagiwara et al,
1999). 
Plasmids 
The HA-tagged p53 expression vector pcDNA-HAp53 was
constructed by inserting the BamHl/Xbal PCR fragment containing
the open reading frame of p53 cDNA using pBRBOSwt (Kanda et
al, 1994) as a template into pcDNA3 (Invitrogen, Carlsbad, CA).
The HA-tagged p73L expression vector was also constructed by
PCR-based method using the full length murine p73L cDNA, which
we reported previously (Senoo et al, 1998), to generate pcDNA-
HAp73L. The HA-tagged p51 expression vector pcDNA-HAp51
was also constructed by RT-PCR followed by HA-tagging from
murine testis cDNA. DN fragment was PCR-amplified using
pcDNA-HAp73L as a template with the following primer pairs: 
5¢-CGGGATCCATGTTGTACCTGGAAAACAATGCCCAGA-
CTCAATTTAGTGAGTATTCCACCGAACTGAAGAAGC-3 ¢ and
5¢-AAATTGGACGTCTGTTCATT-3¢. The HA-tagged DNp73L
expression vector pcDNA-HADNp73L was constructed by
replacement of the BamHl/EcoRl fragment from pcDNA-HAp73L
with the HA-tagged DN fragment generated by second ampli-
fication of DN fragment with the following primer pairs: 
5¢-CGGGATCCATGTACCCATACGATGTTCCAGATTAC-
GCTTGTACCTGGAAAACAATG-3¢ and 5¢-AAATTGGACGT-
CTGTTCATT-3¢. All the sequences amplified by PCR reaction inthis study were confirmed as having no mutation by direct
sequencing. 
Transient transfections and luciferase assays 
For luciferase assay, Cos-7 cells and DLD1 cells grown to ~80%
confluence were co-transfected by SuperFect reagent (Qiagen)
with the following amounts of expression and reporter plasmids in
24-well culture plates. In Cos-7 cells, a SV40-promoter driven
luciferase reporter plasmid pGL2 (0.3 mg, Promega, Madison, Wl)
and a p53-responsive luciferase reporter plasmid PG13 (0.3 mg)
plus pcDNA-HAp51 (0.6 mg) were co-transfected with certain
amounts of pcDNA-HAp73L (0-5 mg) or pcDNA-HADNp73L 
(0-5 mg). In DLD-1 cells, p53-responsive luciferase reporter
plasmid PG13 (0.3 mg) plus pcDNA-HAp53 (0.6 mg) or pcDNA-
HAp51 (0.6 mg) were co-transfected with increasing amounts of
pcDNA-HAp73L (0.6, 1.8 mg) or pcDNA-HADNp73L (0.6, 1.8
mg). The activities of Firefly luciferase were measured 24–36
hours post transfection using the Dual-Luciferase reporter assay
system (Promega). The transfection efficiency was normalized by
the Renilla luciferase activity by the pRLTK (0.3 mg, Promega)
and the relative luciferase activity was calculated in each measure-
ment by the formula: (Firefly luciferase activity)/ (Renilla
luciferase activity). 
RESULTS AND DISCUSSION 
The expression profile of p51/p73L transcripts in
human tumour cell lines 
The p73L/p63/p51/p40/KET gene produces two major isoforms, p51
and p73L, with different amino terminal regions as shown in Figure 1
(see also Table 1). To determine the distinct expression of these two
isoforms in tumour cells, we prepared specific oligonucleotide
primer sets to amplify each of the amino terminal regions (see Figure
1 for primer locations). Using nested RT-PCR/Southern blot analysis,
we examined 29 human tumour cell lines in which the p53 status is
well characterized as wild-type or mutant. As summarized in Table 3,
the profile of p51/p73L expression was not closely correlated with
the p53 status; p51 expression was increased a little in p53 wild-type
cell lines in comparison to p53 mutants although statistical analysis
showed no significant difference. In addition, tumour cell lines with
mutant p53 lacked p51 expression at a high frequency (13/18 cases,
72%), suggesting that p51 and p53 may suppress the same tumour in
an independent manner (Figure 2, lanes 7–11, 15, 16, 19–21, 24–26).
In regard to p73L, similar results were found between p53 wild-type
and p53 mutant cell lines (Table 3). In these 29 tumour cell lines, a
high proportion of tumours (27/29, 93%) showed the DNA-binding
domain (DBD) which is shared in all isoforms of p73L/p51, but the
amino-terminal regions of p73L and p51 were detectable in only 55%
(16/29) and 41% (12/29), respectively. Among these cell lines, the
dual expression of p73L and p51 was found in only 8 cases out of 29
(28%). It is of note that most colon carcinoma cell lines we examined
(SW620, SW480, HT29 and WiDR) and one breast carcinoma cell
line, SKBR3, did not show any amino terminal regions corre-
sponding to either p51 or p73L even though they showed robust
DBD amplification (Figure 2, lanes 8, 9, 10, 15, 16). These results
indicate that the transcription of the p73L/p63/p51/p40/KET gene is
regulated by multiple promoters or splicing events which presumably
generate more isoforms other than those reported previously
(Augustin et al, 1998; Osada et al, 1998; Senoo et al, 1998; Trink et
al, 1998; Yang et al, 1998). In addition, expression of the
p73L/p63/p51/p40/KET gene was undetectable in Lu99 (lung carci-
noma) and DLD1 (colon carcinoma) (Figure 2, lanes 3 and 11).
Southern blot analysis of genomic DNA from these 2 cell lines
revealed no gross alterations of this gene when the full-length p73L
cDNA was used as a probe (data not shown), indicating that the
p73L/p63/p51/p40/KET gene is transcriptionaly silent in these 2 cell
lines. 
A novel truncated isoform of p73L is preferentially
expressed in squamous cell lines and primary human
squamous carcinomas 
In addition to the expected size for p73L and p51, the truncated
DN-type amino-terminus was detected in several tumour cell lines
(Figure 2, lanes 12, 13, 22, 26–29) which were all derived from
squamous cells except for LNCap, a prostate-derived tumour cell
line. However, such a truncated amino-terminus was not detected
in 22 other tumour cell lines including 7 colon-, 2 breast-, 5 lung-,
and 2 stomach-carcinomas and 3 leukaemias (Figure 2) even in our
high sensitive detection system. By estimating from the size, this
truncated band is considered to occur presumably by splicing out
The p73L/p51 gene in human skin cancers 1237
British Journal of Cancer (2001) 84(9), 1235–1241 © 2001 Cancer Research Campaign
p51
p73L
DNp73L
5TA 5dN 5D1
5D2 3N2
ND 3D
3N1 Cb
Ca
Cg
1 23 4 3’ 5 6 7 8 9 10 11 12 13 14 15
Figure 1 Schematic representations of the p73L / p63 / p51 / p40 / KET gene and the positions of the PCR primer pairs used for RT-PCR / Southern blot
analysis. The structure of the p73L / p63 / p51 / p40 / KET gene and the major post-transcriptional splicing events giving rise to multiple isoforms are based on a
recent study by Yang et al (1998). Exons 4 through 10 are common for all the transcripts (DNA binding domain, grey boxes). Exons 1 through 3 encode the
transactivation domain of p51, while p73L is encoded by exon 3¢ at its amino terminus. The a-type carboxy terminus is encoded by the exons through 14, and
the position of the termination codon is indicated by a solid triangle. In contrast, b- and g-type carboxy termini lack exons 13 and 11 through 14, respectively. A
novel isoform, termed DNp73L, which lacks exon 4 from the primary p73L transcript, is also indicated by a dashed line (see text for details). 5¢ primers 5TA and
5dN are the specific primers in the amino terminal regions of p51 and p73L, respectively. Note that DNp73L can be amplified with the same primer sets as used
for p73L amplification. The primers in the common region among the isoforms are also indicated (3N1, 3N2, 5D1, 5D2 and 3D). The Southern blots were
hybridized with the specific oligonucleotide probes shown in solid bars; probes N and D for the amino termini and the DNA binding domain, respectively 1238 M Senoo et al  
British Journal of Cancer (2001) 84(9), 1235–1241 © 2001 Cancer Research Campaign
exon 4 of the p73L primary transcript without a frameshift, which
was confirmed by direct sequencing of the isolated cDNA frag-
ments (data not shown). Then, we named this novel truncated
isoform ‘DNp73L’. 
To determine whether this DNp73L is expressed in normal squa-
mous cells or specifically in tumours, we examined its expression
profile in human squamous cell carcinomas from the skin and in the
corresponding normal skin tissues. As shown in Figure 3, DNp73L
Table 1 The p73L / p63 / p51 / p40 / KET gene isotypes 
Isotypes Synonyms Amino acid length Exon usage 
p51 TAp63a / p51B / KET 641  1–14 
TAp63b 516 1–12, 14 
TAp63g / p51A 448 1–10, 15 
p73L DNp63a 586 3¢, 4–14 
DNp63b 461 3¢, 4–12, 14 
DNp63g 393 3¢, 4–10, 15 
p40 356 3¢, 4–10 
DNp73L DNp73La 501 3¢, 5–14 
DNp73Lb 376 3¢, 5–12, 14 
DNp73Lg 308 3¢, 5–10, 15 
Major isoforms p51 and p73L as well as newly found DNp73L in this study, their synonyms, amino acid length
and the exon usage are summarized. p51 and p73L start its translation from exon 1 and 3¢, respectively, and
DNp73L is spliced out exon 4 from p73L
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Figure 2 Detection of the p51 / p73L transcripts in various human tumour cell lines by RT-PCR followed by Southern hybridization. Total RNAs were extracted
from 29 human tumour cell lines, and 2 amino termini for p51 and p73L and the common DNA-binding domain (DBD) among all the isoforms were amplified by
nested RT-PCR, electrophoresed in 1.2% agarose gel, and transferred to nylon membranes followed by hybridization with the specific oligonucleotide probes as
described in ‘Materials and Methods’. Details concerning the primer sequences and the expected length of the products are listed in Table 2. The solid and open
triangles on the right of each panel indicate the DNp73L and p73L, respectively. RNA quality was confirmed by amplification of a b-actin amplicon (lowest
panel). The p53 status in each cell line is indicated at the bottom of the panels. *Note that the two cervical cell lines ME180 and HeLa were grouped with p53WT
in this study, although they harbor oncoproteins encoded by human papilloma viruses, which inactivate wild-type p53 
Table 2 Nucleotide sequences of the primers used for nested RT-PCR and the expected length of the
products 
Primera Nucleotide sequence Product size 
5D1 (1st sense) 5¢- CTCCTGAACAGCATGGACCAGC - 3¢ 780 bp 
5D2 (2nd sense) 5¢- ACAGTTCCGACGTGTCCTTC - 3¢ 590 bp 
3D (antisense) 5¢- CTTCGTACCATCACCGTTCTT - 3¢
5TA (sense) 5¢- ATGAATTCCTCAGTCCAGAGG - 3¢ 990/720 bpb
5dN (sense) 5¢- TGCCCAGACTCAATTTAGTG - 3¢ 800/530 bpb
3N1 (1st antisense) 5¢- CTGTCCGAAACTTGCTGCTT - 3¢
3N2 (2nd antisense) 5¢- GGATCTTCTACATACTGGGC - 3¢
a Products generated with primers 5TA and 5dN correspond to p51 and p73L, respectively, and DNp73L is
detectable by the same primer pairs used for p73L (see Figure 1 for details). bThe expected length of the
product is indicated as 1st PCR product/2nd PCR product. was detected only in squamous cell carcinomas (5/13, 39%, middle
panel, lanes 8, 9, 11, 17, 19) but never detectable in normal skin
tissues in our highly sensitive detection system (middle panel, lanes
1–6). In addition, we did not detect this novel isoform in the other
primary tissue specimens such as 16 stomach-, 19 breast-, 10
ovarian-cancers as well as the corresponding normal samples (data
not shown). These results strongly suggest that the expression of
DNp73L is highly associated with the carcinogenesis of skin tissue.
On the other hand, while p51 was detected in all normal skin tissues,
its expression in the carcinomas was found at a relatively low
frequency (4/13, 31%). Among these p51-expressing squamous cell
carcinomas, however, the expression of DNp73L was highly associ-
ated (3/4, 75%), while the majority of p51-lacking tumours were
found not to express DNp73L (7/9, 78%). Similarly, most of the
squamous cell lines expressing DNp73L also expressed p51 but
lacked functional p53 (Figure 2, lanes 12, 27–29). From these data,
it can be speculated that if DNp73L has a dominant-negative func-
tion as p73L does, p51 is the more preferable target of DNp73L than
p53. At the same time, it is also possible to speculate that the dual
expression of p73L and DNp73L may strengthen the tumorigenesis
in p51-expressing tissues. 
DNp73L possesses dominant-negative activity against
p53 and p51 
Since DNp73L still retains the DNA-binding domain (see Figure 1),
we then examined whether DNp73L shares dominant-negative
activities with the authentic p73L against both p53 and p51. To
address this issue, we transfected DLD1 cells with a constant
amount (0.6 mg) of wild-type p53 (Figure 4A, left panel) and p51
(right panel) and varying amounts (0.6 or 1.8 mg) of either p73L
(columns 3, 4, 9 and 10) or DNp73L (columns 5, 6, 11 and 12) as
indicated and assayed for transactivation of the p53-responsive
reporter gene. The dominant-negative activity of DNp73L against
p53 was slightly weaker than that of p73L (Figure 4A, compare
columns 5 and 6 to 3 and 4) but was almost equivalent in a dose-
dependent inhibition of p51 transactivation to the authentic p73L
(Figure 4A, compare columns 11 and 12 to 9 and 10), with the
higher suppressor concentration (1.8 mg) giving an almost back-
ground-like (empty vector) level of reporter signal (Figure 4A,
compare column 12 to 7). The luciferase activity driven by SV40-
promoter was unaffected at around this concentration of expres-
sion vector (Figure 4B, 0-2 mg of expression plasmid). These
results suggest that DNp73L specifically suppresses the transcrip-
tion driven by the p53 / p51-responsive promoter. These data may
also imply that the dominant-negative activity of DNp73L targets
p51 more preferably than p53 (Figure 4A, compare columns 2 and
5 to 8 and 11) compared to the equivalent suppression by p73L on
p53- and p51- transactivation (Figure 4A, compare columns 2 and
3 to 8 and 9). 
Though mutations in the p53 gene have been found mostly in its
DNA-binding domain (Greenblatt et al, 1994; Hainaut et al, 1998),
there was no mutation or frameshift in the DNA-binding domain of
the p73L/p63/p51/p40/KETgene in the squamous cell carcinomas we
examined (data not shown). In contrast, we found the loss of p51
expression and the expression of a novel isoform, DNp73L, in the
squamous carcinomas. Thus, transcriptional dysregulation of this
gene may play a more important role(s) than inactivation of p51 itself
by somatic mutations in the tumorigenesis of squamous cells. From
this point of view, it is also assumed that the inactivation machinery
of the putative tumour suppressor p51 differs from that of p53. 
In contrast to p51 and DNp73L, the expression of p73L was
constitutively detected in all the normal and cancerous specimens
we examined (Figure 3, middle panel, lanes 1–19). On the other
hand, Parsa et al have recently shown that expression of p73L is
gradually decreased during the terminal differentiation of squa-
mous cells (Parsa et al, 1999). As for this discrepancy, we can spec-
ulate that detection of the p73L transcript in the tumour specimens
we examined is saturated in our system due to its high sensitivity.
Since the cancerous specimens we examined were biopsied at a
relatively early stage of tumorigenesis, it would be interesting to
examine the expression profile of DNp73L / p73L / p51 in highly
differentiated squamous carcinomas. Whatever the reason, in order
to clarify the biological significance of DNp73L in tumours
expressing a certain amount of p73L, a more quantitative determi-
nation of p73L / DNp73L at the protein level will be required. 
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Table 3 Expression incidence of p51, p73L, DNp73L as well as the
common DNA binding domain (DBD) of p51, p73L and DNp73L in the p53
wild-type (WT) and p53 mutant (mt) cell lines 
Total (n = 29) p53WT (n = 11) p53mt (n = 18) c2- test 
DBD 27 (94%) 10 (91%) 17 (94%)
p51 12 (41%) 7 (64%) 5 (28%) P < 0.10 
p73L 16 (55%) 5 (46%) 11 (61%) P < 0.50 
DNp73L 7 (24%) 2 (18%) 5 (28%) P < 0.75 
p51
p73L
DNp73L
b-actin
Normal Tumour
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Figure 3 Detection of the p51 / p73L / DNp73L transcripts in primary human skin cancers by nested RT-PCR followed by Southern hybridization. Total RNAs
from 13 primary skin cancers (lanes 7–19) as well as the corresponding 6 normal skin tissues (lanes 1–6) were examined for the expression profile of the p51 /
p73L / DNp73L transcripts. The solid triangle on the right (middle panel) indicates the truncated DN-type amino termini named DNp73L, while the open triangle
indicates the authentic p73L. Note that among cancerous specimens, the expression of p51 was absent in 69% (9 cases out of 13), while DNp73L was
expressed in 39% (5 cases out of 13). A cervical carcinoma cell line, ME180, was used as a positive control for each amplification. Products of RT-PCR
amplification of b-actin served as RNA quality control (lower panel) In summary, we have shown that transcription of the p73L/p63/
p51/p40/KET gene is dysregulated in human squamous cell carci-
nomas of the skin. A novel dominant-negative isoform, termed
DNp73L, was detected in squamous cell carcinoma cell lines as well
as in primary human skin cancer specimens but not in the normal
skin tissues. Conversely, the expression of the potential tumour
suppressor p51 was frequently lost in the cancerous specimens we
examined. Furthermore, our present study using human tumour cell
lines indicated that the p73L/p63/p51/p40/KET gene may be
expressed independently of the p53 status. From these results, we
hypothesize that the p73L/p63/p51/p40/KET gene might contribute
to tumorigenesis in human cancers through its altered expression. To
define the oncogenic properties of p73L/DNp73L and the tumour
suppressive properties of p51, further investigations will be
required. Revealing the down-stream target genes of p51 / p73L and
the epigenetic modification mechanisms of the p73L/p63/p51/p40/
KET gene will help to gain a better understanding of the dual roles
of this gene in tumour biology. 
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Figure 4 The novel isoform DNp73L acts in a dominant-negative manner
toward both p53 and p51 in mammalian cells. (A) Exponentially growing
DLD1 cells were transiently co-transfected by lipofection with 0.6 mg of the
p53 expression vector (left panel, columns 2–6) or the p51 expression vector
(right panel, columns 8–12) together with 0.3 mg of PG13 in the presence of
increasing amounts (0.6 mg or 1.8 mg) of either p73L expression vector (lanes
3, 4, 9 and 10) or DNp73L expression vector (lanes 5, 6, 11 and 12) as
indicated. Lanes 1 and 7 were the results from mock transfectants (empty
vector). The data represent the average of 3 independent experiments.
(B) Exponentially growing Cos-7 cells were transiently co-transfected by
lipofection with 0.3 mg of the SV40 promoter-luciferase gene (pGL2, open
circles) or the p53-responsive luciferase gene (PG13, closed circles) plus
0.6 mg of the p51 expression vector in the presence of increasing amounts of
either p73L expression vector (0-5 mg, left panel) or DNp73L expression
vector (0–5 mg, right panel) as indicated. Results are shown as relative
luciferase activity to control cells transfected with an empty vector. The data
represent the average of 3 independent experiments 
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